"Genetic Modification of Cells Used for Transplant Following Intensive Therapy for Ovarian Cancer and Breast Cancer."

According to an abstract submitted by the authors to the 38th Annual Meeting of the American Society of Hematology, held December 6-10, 1996, in Orlando, Florida, "Peripheral blood or marrow cells were collected from patients with advanced carcinomas of the breast or ovary, and then selected with a CD34 monoclonal antibody column. We then incubated the CD34⁺ cells with a MDR-1 vector under two conditions: 1) suspension in retroviral supernatant for 4 hours, and 2) inoculation on stromal monolayers for 2 days in the presence of IL3 and IL6. The goal of the MDR-1 modification was to make safe the post transplant administration of taxol chemotherapy. Eight of the 20 patients...

Want to see the full article?

• Purchase this article for only $3.00